Omalizumab

Introduction Overview

Generic Name

omalizumab

Brand Name

Xolair

Dosage Form

Autoinjector, Prefilled syringe, Vial for reconstitution

Drug Class

Selective immunosuppressants

Pharmacokinetics

Absorption:
Omalizumab, administered subcutaneously, is absorbed slowly and incompletely from the injection site due to its large molecular size as a monoclonal antibody. Peak serum concentrations are typically reached 7 to 8 days post-injection. The bioavailability of omalizumab following subcutaneous administration is approximately 62%. Factors such as injection site and blood flow can influence absorption rates. Concomitant diseases affecting peripheral circulation may alter pharmacokinetics.

Distribution:
The volume of distribution of omalizumab is relatively small, reflecting its confinement primarily to the vascular and interstitial spaces. The molecular size restricts extensive tissue penetration. Omalizumab binds selectively to free circulating immunoglobulin E (IgE), forming complexes that may temporarily increase total serum IgE levels due to slower clearance of these complexes. The antibody does not significantly distribute into the central nervous system due to the blood-brain barrier.

Metabolism:
Being a monoclonal antibody of the IgG1 subclass, omalizumab is metabolized via proteolytic degradation into small peptides and amino acids. This process occurs ubiquitously in the reticuloendothelial system and is not dependent on the cytochrome P450 enzymatic pathway, thereby minimizing metabolic drug-drug interactions. It does not undergo hepatic metabolism via classic Phase I or II enzymes.

Elimination:
The elimination half-life of omalizumab is approximately 26 days (range 17 to 28 days), consistent with typical IgG antibodies. Clearance occurs primarily via target-mediated elimination where it binds to free IgE, and through normal IgG catabolic pathways. There is no significant renal excretion of intact omalizumab due to its molecular size. The long half-life supports monthly or bimonthly dosing regimens. Anti-drug antibodies are rare and have not been shown to significantly alter clearance in most patients.

Dosage Forms

Available Dosage Forms:
- Xolair Autoinjector: 75 mg/0.5 mL, 150 mg/mL, and 300 mg/2 mL single-dose prefilled devices.
- Xolair Prefilled Syringe: 75 mg/0.5 mL, 150 mg/mL, and 300 mg/2 mL single-dose devices.
- Xolair Single-Dose Vial for Reconstitution: 150 mg lyophilized powder for injection.

Dosages for Adults and Adolescents:
- For moderate-to-severe allergic asthma in patients 12 years and older, dosing ranges from 75 mg to 375 mg subcutaneously every 2 or 4 weeks, adjusted by body weight and serum total IgE levels.
- Chronic spontaneous urticaria patients aged 12 years and older receive 150 mg or 300 mg subcutaneously every 4 weeks, independent of IgE or weight.
- Chronic rhinosinusitis with nasal polyps in adults (18 years and older) is treated with doses between 75 mg and 600 mg every 2 or 4 weeks, based on weight and IgE.
- Reduction of allergic reactions in IgE-mediated food allergy in patients 1 year and older utilizes 75 mg to 600 mg subcutaneously every 2 or 4 weeks, dose determined by IgE and body weight.

Specific Patient Populations:
- Pediatric dosing (1 year and older for food allergies; 6 years and older for asthma) involves careful dosage determination guided by IgE levels and weight.
- For children aged 6 to 11 years, administration is performed by a caregiver; 12 years and older may self-inject under supervision.
- Patients interrupting therapy for more than 1 year require retesting of serum IgE to redefine dose.
- Patients with chronic spontaneous urticaria do not require dose adjustment based on IgE or weight.
- Usage in pregnancy and breastfeeding should be carefully considered with clinical guidance, as safety data are limited.

Comprehensive Clinical Guidelines:
Dosing should be initiated only after serum IgE and body weight measurements, adhering to prescribing information dose tables to optimize efficacy and reduce adverse effects. Injection sites must avoid areas such as the 2-inch zone around the navel, and injections should not be used for acute allergic exacerbations.

Mechanism Of Action

Xolair (omalizumab) is a recombinant DNA-derived humanized monoclonal antibody that selectively targets and binds to the Fc region of free immunoglobulin E (IgE) antibodies circulating in the blood. By binding to the Cε3 domain of IgE, omalizumab prevents free IgE from attaching to high-affinity IgE receptors (FcεRI) on the surface of mast cells and basophils.

This blocking action inhibits the sensitization process of these effector cells, thereby preventing the cross-linking that normally triggers the release of inflammatory mediators like histamine, leukotrienes, and prostaglandins, which are responsible for allergic symptoms. Moreover, omalizumab progressively downregulates FcεRI receptor expression on these cells, leading to diminished cell activation and further suppression of allergic inflammation.

At a cellular and biochemical level, this antibody attenuates the cascade that leads to airway hyperresponsiveness, mucosal edema, and recruitment of additional inflammatory cells. This targeted mechanism is distinct from broad immunosuppressants and focuses specifically on IgE-mediated pathways without significant impact on other immunoglobulin subclasses or general immune competence.

Clinical trials and studies have demonstrated that omalizumab reduces serum free IgE levels rapidly (within hours). However, maximal clinical improvement in conditions like asthma, urticaria, and nasal polyps typically requires weeks to months due to the time needed for receptor downregulation and modulation of inflammatory pathways. Comparatively, omalizumab has a favorable safety and efficacy profile over other systemic immunosuppressive agents and is appropriately classified among selective immunosuppressants due to its targeted mode of action.

Pharmacological Actions

Selective binding and neutralization of free IgE antibodies in circulation.
Prevention of IgE-FcεRI receptor interaction on mast cells and basophils.
Inhibition of allergic mediator release such as histamine and leukotrienes.
Downregulation of IgE receptor (FcεRI) expression on effector cells.
Reduction of airway inflammation and hyperresponsiveness in allergic asthma.
Suppression of chronic urticarial symptoms through modulation of immune pathways.
Adjunctive treatment to reduce nasal polyp size and symptoms by targeted immune modulation.
Decreases risk of allergic reactions, including anaphylaxis, in IgE-mediated food allergy.
Does not affect other immunoglobulin classes (e.g., IgA, IgG), maintaining general immune function.
Long half-life sustaining prolonged suppression of IgE-mediated allergic responses.
Minimal systemic immunosuppression compared to traditional corticosteroids or cytotoxic agents.
Delayed onset of maximal clinical effect due to cellular receptor modulation dynamics.
Improves lung function and asthma control measures in patients refractory to inhaled corticosteroids.
Potential reduction in corticosteroid requirements in allergic asthma management.
Contributes to decreased frequency and severity of allergic exacerbations.

Therapeutic Or Clinical Uses

Management of moderate-to-severe persistent allergic asthma in patients aged 6 years and older inadequately controlled with inhaled corticosteroids.
Treatment of chronic spontaneous urticaria in patients aged 12 years and older who remain symptomatic despite H1 antihistamine therapy.
Add-on maintenance therapy for adults with chronic rhinosinusitis with nasal polyps who have inadequate response to nasal corticosteroids.
Reduction of risk for allergic reactions, including anaphylaxis, in patients aged 1 year and older with IgE-mediated food allergies.
Off-label use in certain IgE-mediated allergic conditions under specialist guidance.
Adjunctive therapy enabling reduction of corticosteroid dose in asthma management.
Prevention of severe allergic reactions upon accidental allergen exposure in food allergy patients.
Improves quality of life in patients suffering from refractory allergic diseases.
Treatment option for patients with comorbid allergic conditions benefiting from systemic IgE suppression.
Potential utilization in investigational settings for other IgE-related hypersensitivity conditions.
Option for patients intolerant to or not responding to conventional therapies such as antihistamines or corticosteroids.
Reduction in asthma exacerbation frequency requiring emergency intervention or hospitalization.
Management of nasal polyposis-related symptoms unresponsive to standard therapies.
Prevention of symptom escalation during allergy seasons or exposure to perennial allergens.
Supportive care in complex allergic disease with multiple triggers and chronic symptoms.

Side Or Adverse Effects

Injection site reactions including bruising, redness, warmth, burning, stinging, itching, swelling, hive formation, pain, or inflammation.
Fatigue and tiredness reported in a subset of patients.
Musculoskeletal pain including joint, arm, and leg pain.
Dizziness and lightheadedness.
Dermatitis and other itchy skin conditions.
Earache or otitis media symptoms.
Rare but potentially severe anaphylactic reactions occurring immediately or delayed up to 4 days post-injection.
Nausea, vomiting, or severe diarrhea.
Neurological symptoms such as numbness or tingling in extremities.
Signs of infection including fever, swollen glands, or malaise.
Occasional bone fractures reported.
Rare cases of hair loss (alopecia), typically transient and reversible.
Possible increased risk of certain cancers, though causal relationship unconfirmed.
Hypersensitivity reactions including urticaria and rash.
Other rare side effects such as blood clot signs, chest pain, or respiratory distress necessitating immediate medical attention.

Precautions

Assess for allergy to omalizumab or any inactive ingredients before initiating therapy.
Monitor for signs of hypersensitivity reactions especially immediately after injection and up to 4 days post-dose.
Use caution in patients with a history of severe allergic reactions or anaphylaxis.
Evaluate pre-existing infections or parasitic infestations prior to therapy initiation.
Consider cancer risk factors as increased incidence noted in clinical trials, though causality is unclear.
Avoid abrupt discontinuation of concomitant corticosteroids to prevent withdrawal symptoms.
Inform patients about the need for frequent monitoring of symptoms and IgE levels where appropriate.
Use carefully in patients with latex allergy as some device components contain natural rubber latex.
Consider potential immunogenicity and develop a plan for periodic assessment of treatment efficacy.
Discourage use for treatment of acute allergic events or asthma exacerbations; not a rescue medication.
Educate patients on proper administration technique and disposal of injection materials.
Adjust dosing intervals and amounts attending to interruptions in treatment exceeding one year.
Be vigilant for signs of parasitic infections, especially in endemic regions.
Pregnancy and breastfeeding use require risk-benefit assessment due to limited safety data.
Evaluate drug interactions and polypharmacy risks, particularly with other immunomodulatory agents.

Warnings

Severe, life-threatening anaphylaxis has been reported immediately and up to several days after injection.
Use in emergency treatment of acute allergic reactions, including anaphylaxis, is contraindicated.
Asthma patients should continue all prescribed asthma medications and not alter treatment schedules without medical advice.
Sudden cessation of oral steroids when used concomitantly can precipitate withdrawal symptoms; tapering is needed.
Cancer occurrence was higher in patients treated with Xolair in clinical studies; monitor patients for new malignancies.
Injection site reactions are common; severe reactions require prompt medical evaluation.
Patients should be observed post-injection for signs of immediate hypersensitivity.
Use cautiously in patients with history of cardiovascular disease, including previous heart attack or stroke.
Avoid use in patients allergic to components of the formulation or devices used for injection.
Do not use in patients with hypersensitivity to omalizumab or excipients.
Avoid using the autoinjector in children under 12 years; only healthcare provider administration recommended.
Exposure of prefilled syringes to temperatures above 25°C compromises product stability and efficacy.
Improper storage leading to freezing of product is contraindicated due to loss of activity.
Patients should be informed about symptoms necessitating emergency care such as chest tightness, throat swelling, or difficulty breathing.
Regular and complete dosing necessary for optimal therapeutic effect; missed doses require prompt attention.

Contraindication

Known hypersensitivity or allergy to omalizumab or any of its inactive ingredients.
Acute bronchospasm or status asthmaticus requiring immediate intervention.
Use for emergency treatment of anaphylaxis or acute severe allergic reactions.
Patients with a history of severe allergic reaction to any omalizumab formulation or device.
Hypersensitivity to the compounds constituting the needle cap in prefilled syringes (natural rubber latex).
Use outside of indicated patient age ranges without medical justification and specialist supervision.
Administration in conditions where IgE is not a contributing pathogenic factor may be contraindicated.
Concomitant use with other immunosuppressants not evaluated; caution warranted.
Known parasitic infections unaddressed prior to therapy initiation.
Pregnancy or lactation without careful risk-benefit assessment due to unknown safety profile.
Patients with active malignancy until clinical assessment excludes risk outweighing benefits.
Improper storage or use of degraded or expired product.
Patients unwilling or unable to comply with monitoring and administration requirements.
Use in non-IgE mediated allergic conditions or other off-label uses where evidence is insufficient.
Known allergy to formulation excipients such as L-arginine hydrochloride, L-histidine, polysorbate 20, or sucrose.

Drug Interactions

Concurrent use with other immunosuppressants may increase risk of infections; monitor carefully.
Patients receiving allergy immunotherapy require close monitoring as combination may affect allergic response.
No significant interactions with cytochrome P450-metabolized drugs due to proteolytic metabolism.
Potential additive effects with systemic corticosteroids; do not abruptly discontinue steroids during co-administration.
Vaccines: No specific contraindications, but immunosuppressive effects warrant evaluation prior to live vaccine administration.
No reported clinically relevant interactions with vitamins or common herbal supplements.
Limited data regarding interaction with biologic agents; caution advised in combined usage.
Concomitant use with antihistamines or leukotriene receptor antagonists does not produce clinically significant interactions.
No interaction with common asthma medications including beta-agonists and inhaled corticosteroids.
Potential for altered immune surveillance in combination with cancer immunotherapies remains undefined.
Drugs affecting IgE levels or Fc receptor expression may modify omalizumab pharmacodynamics.
No evidence of altered plasma concentration or effect when used with antibiotics or antifungals.
Patients using multiple anti-allergic agents should be observed for additive adverse effects.
No significant anticoagulant or antiplatelet interactions reported.
Herbals associated with immune modulation (e.g., echinacea) require clinical vigilance during co-administration.

Preparations Of The Drug

Xolair Autoinjector single-dose prefilled devices: available in strengths of 75 mg/0.5 mL, 150 mg/mL, and 300 mg/2 mL.
Xolair Prefilled Syringe single-dose devices: available in strengths of 75 mg/0.5 mL, 150 mg/mL, and 300 mg/2 mL.
Xolair Single-Dose Vial for Reconstitution: 150 mg lyophilized powder requiring aseptic reconstitution prior to subcutaneous injection.
Inactive ingredients for prefilled syringes and autoinjectors include L-arginine hydrochloride, L-histidine, L-histidine hydrochloride monohydrate, and polysorbate 20.
Inactive ingredients for single-dose vial include L-histidine, L-histidine hydrochloride monohydrate, polysorbate 20, and sucrose.
All preparations require refrigeration at 2°C to 8°C (36°F to 46°F) and protection from light until administration.
Prefilled syringes can be removed and returned to refrigeration for a total of up to 2 days at room temperature.
Autoinjectors should be allowed to reach room temperature before administration without external heat sources.
Solutions must be clear and colorless to pale yellow or brownish; cloudy or particulate-laden preparations must not be used.
Each preparation is intended for single use and must be disposed of in a puncture-resistant sharps container.
Packaging includes clear expiration date labeling; expired products must be discarded.
Devices include safety features to prevent accidental needle sticks and ensure accurate dosing.
Preparation reconstitution requires aseptic techniques and appropriate mixing to ensure complete dissolution for vials.
Patient instructions and education materials accompany preparations to facilitate correct administration.
Storage conditions and handling precautions are detailed in the package insert to preserve drug stability.
The drug is marketed and distributed by Genentech, Inc. and Novartis Pharmaceuticals Corporation.